{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:43:03Z","timestamp":1788799383533,"version":"build-2803163510"},"reference-count":134,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["25-15-00020"],"award-info":[{"award-number":["25-15-00020"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Heart failure (HF) remains a leading cause of morbidity and mortality worldwide, affecting over 30 million individuals, with its prevalence steadily increasing due to population aging. Among its forms, heart failure with preserved ejection fraction (HFpEF) has emerged as a major clinical and public health concern, now accounting for more than half of all HF cases and closely associated with comorbidities such as hypertension, obesity, and diabetes. MicroRNAs (miRNAs) have gained recognition as key regulators of the molecular mechanisms underlying HF, particularly HFpEF, where they modulate interconnected pathways of inflammation, fibrosis, and endothelial dysfunction. This review discusses the mechanisms by which miRNAs contribute to the pathogenesis of HF and examines their potential as both biomarkers and therapeutic targets. By integrating current evidence, it aims to clarify the prognostic significance and clinical applicability of these molecular markers, highlighting their role in advancing personalized strategies for the diagnosis and management of HF.<\/jats:p>","DOI":"10.3390\/ijms262412085","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:00:26Z","timestamp":1765882826000},"page":"12085","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Role of MicroRNAs in the Pathophysiology and Management of Heart Failure: From Molecular Mechanisms to Clinical Application"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9499-5632","authenticated-orcid":false,"given":"Irina","family":"Gilyazova","sequence":"first","affiliation":[{"name":"Department of Medical Genetics and Fundamental Medicine, Faculty of General Medicine, Bashkir State Medical University, 450008 Ufa, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9918-6962","authenticated-orcid":false,"given":"Yanina","family":"Timasheva","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics and Fundamental Medicine, Faculty of General Medicine, Bashkir State Medical University, 450008 Ufa, Russia"},{"name":"Institute of Biochemistry and Genetics, Ufa Federal Research Centre of Russian Academy of Sciences, 450054 Ufa, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8623-7812","authenticated-orcid":false,"given":"Anna","family":"Chumakova","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Genetics, Ufa Federal Research Centre of Russian Academy of Sciences, 450054 Ufa, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulshat","family":"Abdeeva","sequence":"additional","affiliation":[{"name":"Department of Pathological Physiology, Faculty of General Medicine, Bashkir State Medical University, 450008 Ufa, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Plotnikova","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Hospital of the Bashkir State Medical University, 450008 Ufa, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2386-6707","authenticated-orcid":false,"given":"Naufal","family":"Zagidullin","sequence":"additional","affiliation":[{"name":"Department of Propaedeutics of Internal Diseases, Faculty of General Medicine, Bashkir State Medical University, 450008 Ufa, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1161\/CIRCRESAHA.122.320257","article-title":"Heart Failure With Preserved Ejection Fraction: Heterogeneous Syndrome, Diverse Preclinical Models","volume":"130","author":"Roh","year":"2022","journal-title":"Circ. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_3","first-page":"523","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"75","author":"McDonagh","year":"2022","journal-title":"Rev. Esp. De Cardiol. (Engl. Ed.)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCHEARTFAILURE.111.966366","article-title":"Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction","volume":"5","author":"Dunlay","year":"2012","journal-title":"Circulation. Heart Fail."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhu, K., Ma, T., Su, Y., Pan, X., Huang, R., Zhang, F., Yan, C., and Xu, D. (2021). Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.683418"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1016\/j.jacc.2018.04.015","article-title":"Critical Appraisal of the 2018 ACC Scientific Sessions Late-Breaking Trials From a Statistician\u2019s Perspective","volume":"71","author":"Pocock","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","first-page":"993","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular","volume":"371","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ejhf.299","article-title":"Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: Safety and efficacy in patients with and without cardiac resynchronization therapy","volume":"17","author":"Zile","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamacardio.2020.6500","article-title":"Assessing the Role of Rare Genetic Variation in Patients With Heart Failure","volume":"6","author":"Povysil","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chazara, O., Dub\u00e9, M.-P., Wang, Q., Middleton, L., Vitsios, D., Walentinsson, A., Wang, Q.-D., Hansson, K.M., Granger, C.B., and Kjekshus, J. (2023). Assessing the role of rare pathogenic variants in heart failure progression by exome sequencing in 8089 patients. Medrxiv Prepr. Serv. Health Sci.","DOI":"10.1101\/2023.07.28.23293350"},{"key":"ref_11","first-page":"e93","article-title":"Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"146","author":"Raghavan","year":"2022","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41591-020-0800-0","article-title":"Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers","volume":"26","author":"Mars","year":"2020","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Singh, R.B., Singh, J., Bidasee, K., Isaza, A., Rupee, S., Rupee, K., Hanoman, C., Adeghate, E., and Smail, M.M. (2024). Molecular and cellular biology and genetic factors in chronic heart failure. Pathophysiology, Risk Factors, and Management of Chronic Heart Failure, Elsevier.","DOI":"10.1016\/B978-0-12-822972-9.00016-X"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100009","DOI":"10.1016\/j.ajpc.2020.100009","article-title":"Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology","volume":"1","author":"Khera","year":"2020","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"R133","DOI":"10.1093\/hmg\/ddz187","article-title":"Towards clinical utility of polygenic risk scores","volume":"28","author":"Lambert","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1161\/CIRCULATIONAHA.119.041161","article-title":"Genome-Wide Analysis of Left Ventricular Image-Derived Phenotypes Identifies Fourteen Loci Associated With Cardiac Morphogenesis and Heart Failure Development","volume":"140","author":"Aung","year":"2019","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13020-021-00532-0","article-title":"Myocardial protective effect and transcriptome profiling of Naoxintong on cardiomyopathy in zebrafish","volume":"16","author":"Hu","year":"2021","journal-title":"Chin. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1002\/ehf2.14107","article-title":"Clinical impacts of sacubitril\/valsartan on patients eligible for cardiac resynchronization therapy","volume":"9","author":"Huang","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCGEN.122.003834","article-title":"Current State and Future of Polygenic Risk Scores in Cardiometabolic Disease: A Scoping Review","volume":"16","author":"Phulka","year":"2023","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Charidemou, E., Felekkis, K., and Papaneophytou, C. (2025). From Natriuretic Peptides to microRNAs: Multi-Analyte Liquid Biopsy Horizons in Heart Failure. Biomolecules, 15.","DOI":"10.3390\/biom15081189"},{"key":"ref_21","first-page":"60","article-title":"MicroRNA and Cardiovascular Diseases","volume":"37","author":"Demir","year":"2020","journal-title":"Balk. Med. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/aps.2018.30","article-title":"miRNAS in cardiovascular diseases: Potential biomarkers, therapeutic targets and challenges","volume":"39","author":"Zhou","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_23","first-page":"221","article-title":"Advances in MicroRNA therapy for heart failure: Clinical trials, preclinical studies, and controversies","volume":"39","author":"Huang","year":"2025","journal-title":"Drugs Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s13287-019-1451-2","article-title":"Applications of miRNAs in cardiac development, disease progression and regeneration","volume":"10","author":"Pang","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCGENETICS.111.961474","article-title":"Noncoding RNA expression in myocardium from infants with tetralogy of Fallot","volume":"5","author":"Kibiryeva","year":"2012","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/CIRCRESAHA.111.248880","article-title":"MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes","volume":"109","author":"Porrello","year":"2011","journal-title":"Circ. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41467-018-03019-z","article-title":"Loss of microRNA-128 promotes cardiomyocyte proliferation and heart regeneration","volume":"9","author":"Huang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"D\u2019Amato, A., Prosperi, S., Severino, P., Myftari, V., Correale, M., Perrone Filardi, P., Badagliacca, R., Fedele, F., Vizza, C.D., and Palazzuoli, A. (2024). MicroRNA and Heart Failure: A Novel Promising Diagnostic and Therapeutic Tool. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247560"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kennel, P.J., and Schulze, P.C. (2021). A Review on the Evolving Roles of MiRNA-Based Technologies in Diagnosing and Treating Heart Failure. Cells, 10.","DOI":"10.3390\/cells10113191"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gallo, G., Rubattu, S., and Volpe, M. (2024). Mitochondrial Dysfunction in Heart Failure: From Pathophysiological Mechanisms to Therapeutic Opportunities. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052667"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","article-title":"Cardiac metabolism in heart failure: Implications beyond ATP production","volume":"113","author":"Doenst","year":"2013","journal-title":"Circ. Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Micu, M.A., Cozac, D.A., and Scridon, A. (2025). miRNA-Orchestrated Fibroinflammatory Responses in Heart Failure with Preserved Ejection Fraction: Translational Opportunities for Precision Medicine. Diagnostics, 15.","DOI":"10.3390\/diagnostics15182286"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbacli.2016.05.005","article-title":"Epigenetics in heart failure phenotypes","volume":"6","author":"Berezin","year":"2016","journal-title":"BBA Clin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e001633","DOI":"10.1161\/CIRCGENETICS.116.001633","article-title":"Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach","volume":"10","author":"Hage","year":"2017","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12933-023-02057-2","article-title":"Treatment with recombinant Sirt1 rewires the cardiac lipidome and rescues diabetes-related metabolic cardiomyopathy","volume":"22","author":"Costantino","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.5114\/aoms\/169775","article-title":"Cardiac microRNAs: Diagnostic and therapeutic potential","volume":"19","author":"Badacz","year":"2023","journal-title":"Arch. Med. Sci. AMS"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1159\/000479995","article-title":"Mir-21 Promotes Cardiac Fibrosis After Myocardial Infarction Via Targeting Smad7","volume":"42","author":"Yuan","year":"2017","journal-title":"Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Surina, S., Fontanella, R.A., Scisciola, L., Marfella, R., Paolisso, G., and Barbieri, M. (2021). miR-21 in Human Cardiomyopathies. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.767064"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1161\/CIRCEP.112.973214","article-title":"Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure","volume":"5","author":"Cardin","year":"2012","journal-title":"Circulation. Arrhythmia Electrophysiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"107243","DOI":"10.1016\/j.carpath.2020.107243","article-title":"Prevention of heart failure with preserved ejection fraction (HFpEF): Reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics","volume":"49","author":"Buja","year":"2020","journal-title":"Cardiovasc. Pathol. Off. J. Soc. Cardiovasc. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.apsb.2011.04.010","article-title":"Role of microRNAs in cardiac hypertrophy, myocardial fibrosis and heart failure","volume":"1","author":"Dong","year":"2011","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ejhf.495","article-title":"MicroRNAs in heart failure: From biomarker to target for therapy","volume":"18","author":"Vegter","year":"2016","journal-title":"Eur. J. Hear. Fail."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kura, B., Kalocayova, B., Devaux, Y., and Bartekova, M. (2020). Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030700"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12967-016-1011-9","article-title":"Micro-RNA-21 (biomarker) and global longitudinal strain (functional marker) in detection of myocardial fibrotic burden in severe aortic valve stenosis: A pilot study","volume":"14","author":"Fabiani","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"C367","DOI":"10.1152\/ajpcell.00051.2022","article-title":"The microRNA-29 family: Role in metabolism and metabolic disease","volume":"323","author":"Dalgaard","year":"2022","journal-title":"Am. J. physiology. Cell Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13105-021-00814-z","article-title":"Role of the microRNA-29 family in myocardial fibrosis","volume":"77","author":"Li","year":"2021","journal-title":"J. Physiol. Biochem."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Huang, X.H., Li, J.L., Li, X.Y., Wang, S.X., Jiao, Z.H., Li, S.Q., Liu, J., and Ding, J. (2021). miR-208a in Cardiac Hypertrophy and Remodeling. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.773314"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/eurjhf\/hft018","article-title":"Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure","volume":"15","author":"Dickinson","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.21037\/jxym-21-8","article-title":"Potential link between microRNA-208 and cardiovascular diseases","volume":"6","author":"Zhang","year":"2021","journal-title":"J. Xiangya Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00402"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_52","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Topf, A., Mirna, M., Ohnewein, B., Jirak, P., Kopp, K., Fejzic, D., Haslinger, M., Motloch, L.J., Hoppe, U.C., and Berezin, A. (2020). The Diagnostic and Therapeutic Value of Multimarker Analysis in Heart Failure. An Approach to Biomarker-Targeted Therapy. Front. Cardiovasc. Med., 7.","DOI":"10.3389\/fcvm.2020.579567"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1002\/ehf2.15324","article-title":"Multi-microRNA diagnostic panel for heart failure with preserved ejection fraction in preclinical and clinical settings","volume":"12","author":"Parvan","year":"2025","journal-title":"ESC Hear. Fail."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ejhf.2019","article-title":"The HFA-PEFF and H(2) FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction","volume":"23","author":"Henkens","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/clinchem\/hvaa255","article-title":"Being in Two Minds-The Challenge of Heart Failure with Preserved Ejection Fraction Diagnosis with a Single Biomarker","volume":"67","author":"Suthahar","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Shrivastava, A., Haase, T., Zeller, T., and Schulte, C. (2020). Biomarkers for Heart Failure Prognosis: Proteins, Genetic Scores and Non-coding RNAs. Front. Cardiovasc. Med., 7.","DOI":"10.3389\/fcvm.2020.601364"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"104185","DOI":"10.1016\/j.lpm.2023.104185","article-title":"Heart failure with preserved ejection fraction: New challenges and new hopes","volume":"53","author":"Logeart","year":"2024","journal-title":"Presse Medicale"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1161\/CIRCRESAHA.110.218297","article-title":"MiR423-5p as a circulating biomarker for heart failure","volume":"106","author":"Tijsen","year":"2010","journal-title":"Circ. Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Fumarulo, I., De Prisco, A., Salerno, E.N.M., Ravenna, S.E., Vaccarella, M., Garramone, B., Burzotta, F., and Aspromonte, N. (2025). New Frontiers of microRNA in Heart Failure: From Clinical Risk to Therapeutic Applications. J. Clin. Med., 14.","DOI":"10.3390\/jcm14186361"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/eurjhf\/hft078","article-title":"Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients","volume":"15","author":"Ellis","year":"2013","journal-title":"Eur. J. Hear. Fail."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Seronde, M.F., Vausort, M., Gayat, E., Goretti, E., Ng, L.L., Squire, I.B., Vodovar, N., Sadoune, M., Samuel, J.L., and Thum, T. (2015). Circulating microRNAs and Outcome in Patients with Acute Heart Failure. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0142237"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e27206","DOI":"10.1016\/j.heliyon.2024.e27206","article-title":"Profile of serum microRNAs in heart failure with reduced and preserved ejection fraction: Correlation with myocardial remodeling","volume":"10","author":"Paim","year":"2024","journal-title":"Heliyon"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00109-019-01833-6","article-title":"Connecting sex differences, estrogen signaling, and microRNAs in cardiac fibrosis","volume":"97","author":"Medzikovic","year":"2019","journal-title":"J. Mol. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Wang, L., Guo, A., Liang, S., Yu, L., Shen, B., and Huang, Z. (2025). The association of serum hsa-miR-21-5p expression with the severity and prognosis of heart failure with reduced ejection fraction. BMC Cardiovasc. Disord, 25.","DOI":"10.1186\/s12872-024-04465-y"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/01.RES.0000257913.42552.23","article-title":"MicroRNAs play an essential role in the development of cardiac hypertrophy","volume":"100","author":"Sayed","year":"2007","journal-title":"Circ. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"23086","DOI":"10.3390\/ijms141123086","article-title":"Let-7 in cardiovascular diseases, heart development and cardiovascular differentiation from stem cells","volume":"14","author":"Bao","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e70196","DOI":"10.1096\/fj.202302587RRR","article-title":"Cardiomyocyte-derived small extracellular vesicle-transported let-7b-5p modulates cardiac remodeling via TLR7 signaling pathway","volume":"38","author":"Zhang","year":"2024","journal-title":"FASEB J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/cvr\/cvz215","article-title":"Circular RNA circRNA_000203 aggravates cardiac hypertrophy via suppressing miR-26b-5p and miR-140-3p binding to Gata4","volume":"116","author":"Li","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/10408363.2022.2128030","article-title":"Development of circulating microRNA-based biomarkers for medical decision-making: A friendly reminder of what should NOT be done","volume":"60","author":"Lakkisto","year":"2023","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10741-023-10369-4","article-title":"Sex-specific differences in risk factors comorbidities, diagnostic challenges, optimal management, and prognostic outcomes of heart failure with preserved ejection fraction: A comprehensive literature review","volume":"29","author":"Abubakar","year":"2024","journal-title":"Hear. Fail. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Mamtani, M.R., Thakre, T.P., Kalkonde, M.Y., Amin, M.A., Kalkonde, Y.V., Amin, A.P., and Kulkarni, H. (2006). A simple method to combine multiple molecular biomarkers for dichotomous diagnostic classification. BMC Bioinform., 7.","DOI":"10.1186\/1471-2105-7-442"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"102813","DOI":"10.1016\/j.bspc.2021.102813","article-title":"A review of machine learning in hypertension detection and blood pressure estimation based on clinical and physiological data","volume":"68","author":"Montesinos","year":"2021","journal-title":"Biomed. Signal Process. Control."},{"key":"ref_74","first-page":"e37929","article-title":"Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: A systematic review and meta-analysis","volume":"10","author":"Parvan","year":"2022","journal-title":"Eur. J. Hear. Fail."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e37929","DOI":"10.1016\/j.heliyon.2024.e37929","article-title":"Potential diagnostic value of circulating miRNAs in HFrEF and bioinformatics analysis","volume":"10","author":"Kuai","year":"2024","journal-title":"Heliyon"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.7150\/thno.22878","article-title":"MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of cardiac hypertrophy following mechanical stress","volume":"8","author":"Yuan","year":"2018","journal-title":"Theranostics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.hjc.2017.10.002","article-title":"Circulating microRNAs as novel biomarkers for heart failure","volume":"59","author":"Chen","year":"2018","journal-title":"Hell. J. Cardiol. HJC Hell. Kardiol. Ep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1159\/000459899","article-title":"Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure","volume":"41","author":"Xiao","year":"2017","journal-title":"Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.114.013220","article-title":"Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study","volume":"131","author":"Melman","year":"2015","journal-title":"Circulation"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ejhf.961","article-title":"Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure","volume":"20","author":"Masson","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/eurjhf\/hft088","article-title":"Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: Responders vs. non-responders","volume":"15","author":"Marfella","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/cvr\/cvs001","article-title":"GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy","volume":"93","author":"Han","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Li, R., Yan, G., Li, Q., Sun, H., Hu, Y., Sun, J., and Xu, B. (2012). MicroRNA-145 protects cardiomyocytes against hydrogen peroxide (H2O2)-induced apoptosis through targeting the mitochondria apoptotic pathway. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044907"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/hep.25613","article-title":"Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis","volume":"56","author":"Lakner","year":"2012","journal-title":"Hepatology"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Bagnall, R.D., Tsoutsman, T., Shephard, R.E., Ritchie, W., and Semsarian, C. (2012). Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044744"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/CIRCRESAHA.108.182535","article-title":"miR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling","volume":"104","author":"Duisters","year":"2009","journal-title":"Circ. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1152\/physiolgenomics.00145.2010","article-title":"MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats","volume":"43","author":"Soci","year":"2011","journal-title":"Physiol. Genom."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1681\/ASN.2011010055","article-title":"Suppression of microRNA-29 expression by TGF-\u03b21 promotes collagen expression and renal fibrosis","volume":"23","author":"Wang","year":"2012","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Tanase, D.M., Gosav, E.M., Ouatu, A., Badescu, M.C., Dima, N., Ganceanu-Rusu, A.R., Popescu, D., Floria, M., Rezus, E., and Rezus, C. (2021). Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI). Life, 11.","DOI":"10.3390\/life11101057"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/cvr\/cvab210","article-title":"Circulating microRNAs predispose to takotsubo syndrome following high-dose adrenaline exposure","volume":"118","author":"Couch","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Sutanto, H., Dobrev, D., and Heijman, J. (2021). Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168994"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/jpet.121.001251","article-title":"Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes","volume":"384","author":"Mone","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"109063","DOI":"10.1016\/j.jdiacomp.2025.109063","article-title":"Effects of empagliflozin and dapagliflozin, SGLT2 inhibitors, on miRNA expressions in diabetes-related cardiovascular damage in rats","volume":"39","author":"Polat","year":"2025","journal-title":"J. Diabetes Complicat."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ejhf.223","article-title":"Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction","volume":"17","author":"Wong","year":"2015","journal-title":"Eur. J. Hear. Fail."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cardfail.2013.01.007","article-title":"The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study: Rationale and design","volume":"19","author":"Santhanakrishnan","year":"2013","journal-title":"J. Card. Fail."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Wu, Y., Pan, N., An, Y., Xu, M., Tan, L., and Zhang, L. (2020). Diagnostic and Prognostic Biomarkers for Myocardial Infarction. Front. Cardiovasc. Med., 7.","DOI":"10.3389\/fcvm.2020.617277"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1152\/japplphysiol.01123.2014","article-title":"High-intensity interval training attenuates endothelial dysfunction in a Dahl salt-sensitive rat model of heart failure with preserved ejection fraction","volume":"119","author":"Adams","year":"2015","journal-title":"J. Appl. Physiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e89169","DOI":"10.1172\/jci.insight.89169","article-title":"Myocardial microRNAs associated with reverse remodeling in human heart failure","volume":"2","author":"Sucharov","year":"2017","journal-title":"JCI Insight"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1038\/s41598-021-84707-7","article-title":"Circulating miR-21, miR-29a, and miR-126 are associated with premature death risk due to cancer and cardiovascular disease: The JACC Study","volume":"11","author":"Yamada","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-022-01458-z","article-title":"MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes","volume":"21","author":"Veitch","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.yjmcc.2024.11.004","article-title":"Inhibition of miR-92a normalizes vascular gene expression and prevents diastolic dysfunction in heart failure with preserved ejection fraction","volume":"198","author":"Kattih","year":"2025","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Dominic, K.L., Schmidt, A.V., Granzier, H., Campbell, K.S., and Stelzer, J.E. (2024). Mechanism-based myofilament manipulation to treat diastolic dysfunction in HFpEF. Front. Physiol., 15.","DOI":"10.3389\/fphys.2024.1512550"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Su, T., Shao, X., Zhang, X., Han, Z., Yang, C., and Li, X. (2019). Circulating microRNA-1 in the diagnosis and predicting prognosis of patients with chest pain: A prospective cohort study. BMC Cardiovasc. Disord, 19.","DOI":"10.1186\/s12872-018-0987-x"},{"key":"ref_106","first-page":"8840","article-title":"Combined Use of Circulating miR-133a and NT-proBNP Improves Heart Failure Diagnostic Accuracy in Elderly Patients","volume":"24","author":"Guo","year":"2018","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e27779","DOI":"10.1097\/MD.0000000000027779","article-title":"Circulating microRNA-208 family as early diagnostic biomarkers for acute myocardial infarction: A meta-analysis","volume":"100","author":"Wang","year":"2021","journal-title":"Medicine"},{"key":"ref_108","first-page":"303","article-title":"Circulating miR-499 are novel and sensitive biomarker of acute myocardial infarction","volume":"7","author":"Zhang","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Parvan, R., Becker, V., Hosseinpour, M., Moradi, Y., Louch, W.E., Cataliotti, A., Devaux, Y., Frisk, M., and Silva, G.J.J. (2025). Prognostic and predictive microRNA panels for heart failure patients with reduced or preserved ejection fraction: A meta-analysis of Kaplan-Meier-based individual patient data. BMC Med., 23.","DOI":"10.1186\/s12916-025-04238-0"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Gager, G.M., Eyileten, C., Postu\u0142a, M., Nowak, A., G\u0105secka, A., Jilma, B., and Siller-Matula, J.M. (2023). Expression Patterns of MiR-125a and MiR-223 and Their Association with Diabetes Mellitus and Survival in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041118"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Han, Q., Zhang, L., and Liao, R. (2024). Diagnostic and prognostic significance of miR-320a-3p in patients with chronic heart failure. BMC Cardiovasc. Disord, 24.","DOI":"10.1186\/s12872-024-03966-0"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1038\/s41598-020-61836-z","article-title":"Circulating miRNA-21 as a diagnostic biomarker in elderly patients with type 2 cardiorenal syndrome","volume":"10","author":"Wang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Xue, S., Liu, D., Zhu, W., Su, Z., Zhang, L., Zhou, C., and Li, P. (2019). Circulating MiR-17-5p, MiR-126-5p and MiR-145-3p Are Novel Biomarkers for Diagnosis of Acute Myocardial Infarction. Front. Physiol., 10.","DOI":"10.3389\/fphys.2019.00123"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e27744","DOI":"10.1097\/MD.0000000000027744","article-title":"Prognostic value of microRNAs in heart failure: A meta-analysis","volume":"100","author":"Yang","year":"2021","journal-title":"Medicine"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"10760296211050642","DOI":"10.1177\/10760296211050642","article-title":"Diagnostic and Prognostic Significance of serum miR-18a-5p in Patients with Atherosclerosis","volume":"27","author":"Teng","year":"2021","journal-title":"Clin. Appl. Thromb.\/Hemost. Off. J. Int. Acad. Clin. Appl. Thromb.\/Hemost."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"20355","DOI":"10.3390\/ijms151120355","article-title":"Circulating microRNA-19a as a potential novel biomarker for diagnosis of acute myocardial infarction","volume":"15","author":"Zhong","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e13308","DOI":"10.1111\/eci.13308","article-title":"Diagnostic value of circulating microRNA-19b in heart failure","volume":"50","author":"Zhang","year":"2020","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"42916","DOI":"10.1038\/srep42916","article-title":"Circulating miR-155, miR-145 and let-7c as diagnostic biomarkers of the coronary artery disease","volume":"7","author":"Faccini","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3892\/etm.2021.10796","article-title":"Differentially expressed TUG1 and miR-145-5p indicate different severity of chronic heart failure and predict 2-year survival prognosis","volume":"22","author":"Zhu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_120","first-page":"76","article-title":"Role of micro-RNAs 21, 124 and other novel biomarkers in distinguishing between group 1 WHO pulmonary hypertension and group 2, 3 WHO pulmonary hypertension","volume":"75","author":"Dimitry","year":"2023","journal-title":"Egypt. Heart J. (EHJ) Off. Bull. Egypt. Soc. Cardiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"104179","DOI":"10.1016\/j.drudis.2024.104179","article-title":"MicroRNAs and therapeutic potentials in acute and chronic cardiac disease","volume":"29","author":"Song","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_122","first-page":"724","article-title":"Analysis of the diagnostic and prognostic value of miR-9-5p in carotid artery stenosis","volume":"21","author":"Liu","year":"2021","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"6853939","DOI":"10.1155\/2022\/6853939","article-title":"lncRNA ROR and miR-125b Predict the Prognosis in Heart Failure Combined Acute Renal Failure","volume":"2022","author":"Xue","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Sc\u0103rl\u0103tescu, A.I., Barb\u0103lat\u0103, T., Sima, A.V., Stancu, C., Niculescu, L., and Micheu, M.M. (2022). miR-146a-5p, miR-223-3p and miR-142-3p as Potential Predictors of Major Adverse Cardiac Events in Young Patients with Acute ST Elevation Myocardial Infarction-Added Value over Left Ventricular Myocardial Work Indices. Diagnostics, 12.","DOI":"10.3390\/diagnostics12081946"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Vita, G.L., Aguennouz, M., Polito, F., Oteri, R., Russo, M., Gentile, L., Barbagallo, C., Ragusa, M., Rodolico, C., and Di Giorgio, R.M. (2020). Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis. Front. Mol. Neurosci., 13.","DOI":"10.3389\/fnmol.2020.00102"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e24138","DOI":"10.1002\/jcla.24138","article-title":"MicroRNA-34a in coronary heart disease: Correlation with disease risk, blood lipid, stenosis degree, inflammatory cytokines, and cell adhesion molecules","volume":"36","author":"Li","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_127","first-page":"347","article-title":"Circulating microRNA-126 as an Independent Risk Predictor of Coronary Artery Disease: A Case-Control Study","volume":"32","author":"Ali","year":"2021","journal-title":"Ejifcc"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"BSR20191234","DOI":"10.1042\/BSR20191234","article-title":"MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy","volume":"40","author":"Huang","year":"2020","journal-title":"Biosci. Rep."},{"key":"ref_129","first-page":"1985","article-title":"The diagnostic value of circulating microRNAs in heart failure","volume":"17","author":"Huang","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_130","first-page":"3348","article-title":"Long noncoding RNA PVT1 contributes to vascular endothelial cell proliferation via inhibition of miR-190a-5p in diagnostic biomarker evaluation of chronic heart failure","volume":"19","author":"Sun","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e6825","DOI":"10.1097\/MD.0000000000006825","article-title":"miRNAs as biomarkers for diagnosis of heart failure: A systematic review and meta-analysis","volume":"96","author":"Yan","year":"2017","journal-title":"Medicine"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13019-024-03091-1","article-title":"Diagnostic and prognostic value of microRNA423-5p in patients with heart failure","volume":"19","author":"Guo","year":"2024","journal-title":"J. Cardiothorac. Surg."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"73","DOI":"10.15825\/1995-1191-2021-3-73-81","article-title":"Diagnostic value of microRNA-27 and -339 in heart transplant recipients with myocardial fibrosis","volume":"23","author":"Shevchenko","year":"2021","journal-title":"Russ. J. Transplantology Artif. Organs"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Sadat-Ebrahimi, S.R., Rezabakhsh, A., Aslanabadi, N., Asadi, M., Zafari, V., Shanebandi, D., Zarredar, H., Enamzadeh, E., Taghizadeh, H., and Badalzadeh, R. (2022). Novel diagnostic potential of miR-1 in patients with acute heart failure. PLoS ONE, 17, Erratum in PLoS ONE. 2025, 20, e0320341.","DOI":"10.1371\/journal.pone.0320341"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12085\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:01:17Z","timestamp":1765882877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":134,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262412085"],"URL":"https:\/\/doi.org\/10.3390\/ijms262412085","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}